Journal Mobile Options
Table of Contents
Vol. 42, No. 1, 1999
Issue release date: July 1999

Gabapentin as Treatment for Hemifacial Spasm

Bandini F. · Mazzella L.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Hemifacial spasm, a life-long condition characterized by involuntary unilateral contractions of the facial muscles, is a disabling disorder often resulting in patient irritation and social embarassment. Its probable etiology is neurovascular compression of the facial nerve at its root exit zone. The current medical treatment consists of either baclofen or anticonvulsant drugs, with limitation due to side effects or low efficacy. In recent years botulinum toxin injection and microvascular decompression of the facial nerve have been shown to be highly successful. However, both procedures share some complications and require special techniques. We present 5 patients affected by hemifacial spasm who responded well to the novel anticonvulsant drug gabapentin. Gabapentin was administered at a dose ranging from 900 to 1,600 mg daily, with rapid and clear improvement of spasms and absence of any remarkable adverse effects. Our findings suggest that gabapentin may be an effective treatment for patients with hemifacial spasm with a very good ratio of therapeutic effects to side effects when compared with other drugs currently used.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Rosner H, Rubin L, Kestenbaum A: Gabapentin adjunctive therapy in neuropathic pain. Clin J Pain 1996;12:56–58.
  2. Graul AI: Focus on present and future migraine therapy. Drug News Perspect 1996;9:560–561.
  3. Averbuch-Heller L, Tusa RJ, Fuhry L, Rottach KG, Ganser GL, Heide W, Büttner U, Leigh RJ: A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol 1997;41:818–825.
  4. Priebe MM, Sherwood AM, Graves DE, Olson WH: Effectiveness of gabapentin in controlling spasticity: A quantitative study. Spinal Cord 1997;35:171–175.
  5. Young LT, Robb JC, Patelis-Siotis D, Mac Donald C, Joffe RT: Acute treatment of bipolar depression with gabapentin. Biol Psychiatry 1997;42:851–853.

    External Resources

  6. Neilsen VK: Pathophysiology of hemifacial spasm. I. Ephaptic transmission and ectopic excitation. Neurology 1984;34:418–426.

    External Resources

  7. Moller AR: Hemifacial spasm: Ephaptic transmission or hyperexcitability of the facial motor nucleus. Exp Neurol 1987;98:110–119.

    External Resources

  8. Mellik GA: Hemifacial spasm: Successful treatment with felbamate. J Pain Symptom Manage 1995;10:392–395.
  9. Gross ML: Hemifacial spasm: Treatment with pizotifen. J Neurol Neurosurg Psychiatry 1996;61:118.
  10. Brin MF, Jankovic J, Comella C, Blitzer A, Tsui J, Pullman SL: Treatment of dystonia using botulinum toxin; in Kurlan R (ed): Treatment of Movement Disorders. Philadelphia, Lippincott, 1995, pp 183–246.
  11. Wirtschafter JD, McLoon LK: Long-term efficacy of local doxorubicin chemomyectomy in patients with blepharospasm and hemifacial spasm. Ophthalmology 1998;105:342–346.
  12. Barker FG II, Jannetta PJ, Bissonette DJ, Shields PT, Larkins MV, Jho HD: Microvascular decompression for hemifacial spasm. J Neurosurg 1995;82:201–210.
  13. Payner TD, Tew JM: Recurrence of hemifacial spasm after microvascular decompression. Neurosurgery 1996;38:686–690.
  14. Illingworth RD, Porter DG, Jakubowski J: Hemifacial spasm: A prospective long-term follow up of 83 cases treated by microvascular decompression at two neurosurgical centres in the United Kingdom. J Neurol Neurosurg Psychiatry 1996;60:72–77.
  15. Taylor CP: Gabapentin: Mechanisms of action; in Levy RH, Mattson RH, Meldrum BS (eds): Antiepileptic Drugs. New York, Raven Press, 1995, pp 829–841.
  16. Löscher W, Hönack D, Taylor CP: Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of the rat brain. Neurosci Lett 1991;128:150–154.
  17. Honmou O, Oyelese AA, Kocsis JD: The anticonvulsant gabapentin enhances promoted release of GABA in hippocampus: A field potential analysis. Brain Res 1995;692:273–277.

    External Resources

  18. Patel J, Naritoku DK: Gabapentin for the treatment of hemifacial spasm. Clin Neuropharmacol 1996;19:185–188.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00